期刊文献+

Low red blood cell levels of deglycating enzymes in colorectal cancer patients 被引量:1

Low red blood cell levels of deglycating enzymes in colorectal cancer patients
下载PDF
导出
摘要 AIM: To investigate Glyoxalase Ⅰ and fructosamine-3-kinase (FN3K) activity in red blood cells from patients with colorectal adenomas and cancer. METHODS: Thirty three consecutive subjects with one or more histologically confirmed colorectal adenomatous polyps, 16 colorectal cancer patients and a group of 11 control subjects with normal colonoscopy were included in the study. Glyoxalase Ⅰ and FN3K activities were measured in red blood cells using a spectrophotometric and radiometric assay, respectively. RESULTS: A significant reduction in both Glyoxalase Ⅰ and FN3K activity was detected in patients with tumors compared to patients with adenomas and the controls. Erythrocyte Glyoxalase Ⅰ activity in colorectal cancer was approximately 6 times lower than that detected in patients with adenoma (0.022 ± 0.01 mmol/min per milliliter vs 0.128 ± 0.19 mmol/min per milliliter of red blood cells, P = 0.003, Tukey's test). FN3K activity in red blood cells from patients with colon cancer was approximately 2 times lower than that detected in adenoma patients (19.55 ± 6.4 pmol/min per milliliter vs 38.6 ± 31.7 pmol/min per milliliter of red blood cells, P = 0.04, Tukey's test). CONCLUSION: These findings suggest that deglycating enzymes may be involved in the malignant transformation of colon mucosa. AIM: To investigate Glyoxalase Ⅰ and fructosamine-3-kinase (FN3K) activity in red blood cells from patients with colorectal adenomas and cancer. METHODS: Thirty three consecutive subjects with one or more histologically confirmed colorectal adenomatous polyps, 16 colorectal cancer patients and a group of 11 control subjects with normal colonoscopy were included in the study. Glyoxalase Ⅰ and FN3K activities were measured in red blood cells using a spectrophotometric and radiometric assay, respectively. RESULTS: A significant reduction in both Glyoxalase Ⅰ and FN3K activity was detected in patients with tumors compared to patients with adenomas and the controls. Erythrocyte Glyoxalase Ⅰ activity in colorectal cancer was approximately 6 times lower than that detected in patients with adenoma (0.022 ± 0.01 mmol/min per milliliter vs 0.128 ± 0.19 mmol/min per milliliter of red blood cells, P = 0.003, Tukey’s test). FN3K activity in red blood cells from patients with colon cancer was approximately 2 times lower than that detected in adenoma patients (19.55 ± 6.4 pmol/min per milliliter vs 38.6 ± 31.7 pmol/min per milliliter of red blood cells, P = 0.04, Tukey’s test). CONCLUSION: These findings suggest that deglycating enzymes may be involved in the malignant transformation of colon mucosa.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第3期329-333,共5页 世界胃肠病学杂志(英文版)
关键词 癌症患者 细胞水平 大肠癌 激酶 红血细胞 辐射检测 活性检测 乙二醛 Colorectal cancer Enzymatic activity Fructosamine-3-kinase Glycation Glyoxalase Ⅰ
  • 相关文献

参考文献1

二级参考文献59

  • 1Zimmet P,Magliano D,Matsuzawa Y,Alberti G,Shaw J.The metabolic syndrome:a global public health problem and a new definition.J Atheroscler Thromb 2005; 12:295-300.
  • 2Vague J.La differenciation sexuelle,facteur determinant des formes de l'obesite.Presse Med 1947; 55:339.
  • 3Grundy SM,Cleeman JI,Daniels SR,Donato KA,Eckel RH,Franklin BA,Gordon DJ,Krauss RM,Savage PJ,Smith SC Jr,Spertus JA,Costa F.Diagnosis and management of the metabolic syndrome:an American Heart Association/ National Heart,Lung,and Blood Institute Scientific Statement.Circulation 2005; 112:2735-2752.
  • 4Kahn R,Buse J,Ferrannini E,Stern M.The metabolic syndrome:time for a critical appraisal:joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care 2005; 28:2289-2304.
  • 5Flegal KM,Carroll MD,Ogden CL,Johnson CL.Prevalence and trends in obesity among US adults,1999-2000.JAMA 2002; 288:1723-1727.
  • 6Martínez MA,Puig JG,Mora M,Aragón R,O'Dogherty P,Antón JL,Sánchez-Villares T,Rubio JM,Rosado J,Torres R,Marcos J,Pallardo LF,Banegas JR.Metabolic syndrome:prevalence,associated factors,and C-reactive protein:the MADRIC (MADrid Riesgo Cardiovascular) Study.Metabolism 2008; 57:1232-1240.
  • 7Hildrum B,Mykletun A,Hole T,Midthjell K,Dahl AA.Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program:the Norwegian HUNT 2 study.BMC Public Health 2007; 7:220.
  • 8Cameron AJ,Shaw JE,Zimmet PZ.The metabolic syndrome:prevalence in worldwide populations.Endocrinol Metab Clin North Am 2004; 33:351-375,table of contents.
  • 9Ninomiya JK,L'Italien G,Criqui MH,Whyte JL,Gamst A,Chen RS.Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.Circulation 2004; 109:42-46.
  • 10Eckel RH,Grundy SM,Zimmet PZ.The metabolic syndrome.Lancet 2005; 365:1415-1428.

共引文献15

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部